0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gui (RCT) 0% 1.00 [0.28-3.56] death 4/25 4/25 HFRS, Hantann Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Early treatment 0% 1.00 [0.28-3.56] 4/25 4/25 no change All studies 0% 1.00 [0.28-3.56] 4/25 4/25 no change 1 interferon-α hantavirus study c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome, see appendix) Favors interferon-α Favors control
Interferon-α (IFNa) is a recombinant type I interferon cytokine with antiviral and immunomodulatory activity, administered subcutaneously, intramuscularly, or by nebulization, that induces interferon-stimulated genes to inhibit viral replication and modulate the host innate immune response.
May 1
1987
 Gui et al., Journal of Infectious Diseases, doi:10.1093/infdis/155.5.1047 Hemorrhagic Fever with Renal Syndrome: Treatment with Recombinant Interferon
32% worse recovery (p<0.0001). RCT 50 hospitalized patients with hemorrhagic fever with renal syndrome (HFRS) showing no significant benefit with recombinant alpha-2 interferon treatment. Mortality was identical in both groups (16% each, 4 deaths per group). The interf..